Cesar A. Santa‐Maria

4.0k total citations
67 papers, 1.9k citations indexed

About

Cesar A. Santa‐Maria is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Cesar A. Santa‐Maria has authored 67 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Oncology, 32 papers in Pulmonary and Respiratory Medicine and 23 papers in Cancer Research. Recurrent topics in Cesar A. Santa‐Maria's work include Cancer Immunotherapy and Biomarkers (19 papers), Advanced Breast Cancer Therapies (18 papers) and Cancer Treatment and Pharmacology (13 papers). Cesar A. Santa‐Maria is often cited by papers focused on Cancer Immunotherapy and Biomarkers (19 papers), Advanced Breast Cancer Therapies (18 papers) and Cancer Treatment and Pharmacology (13 papers). Cesar A. Santa‐Maria collaborates with scholars based in United States, China and Brazil. Cesar A. Santa‐Maria's co-authors include William J. Gradishar, Massimo Cristofanilli, Gabriel N. Hortobágyi, Francisco J. Esteva, Young Kwang Chae, Francis J. Giles, Ami N. Shah, Benedito A. Carneiro, Sarika Jain and Hua Guo and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Cesar A. Santa‐Maria

64 papers receiving 1.8k citations

Peers

Countries citing papers authored by Cesar A. Santa‐Maria

Since Specialization

Citations

This map shows the geographic impact of Cesar A. Santa‐Maria's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cesar A. Santa‐Maria with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cesar A. Santa‐Maria more than expected).

Fields of papers citing papers by Cesar A. Santa‐Maria

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cesar A. Santa‐Maria. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cesar A. Santa‐Maria. The network helps show where Cesar A. Santa‐Maria may publish in the future.

Co-authorship network of co-authors of Cesar A. Santa‐Maria

This figure shows the co-authorship network connecting the top 25 collaborators of Cesar A. Santa‐Maria. A scholar is included among the top collaborators of Cesar A. Santa‐Maria based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cesar A. Santa‐Maria. Cesar A. Santa‐Maria is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Machine Learning–Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2− Early Breast Cancer Using Real-World and NATALEE Data 2025 ·Clinical Cancer Research ·Frederick M. Howard, Peter A. Fasching, Cesar A. Santa‐Maria, Elgene Lim, Joseph A. Sparano, Maryam B. Lustberg, Thomas Bachelot, Oleg Blyuss, Christine Brezden‐Masley, Yeon Hee Park, (unknown), (unknown), (unknown), Christoph Kurz, Patricia Domínguez Castro, Pedram Razavi	1
2	Virtual patient analysis identifies strategies to improve the performance of predictive biomarkers for PD-1 blockade 2024 ·Proceedings of the National Academy of Sciences ·(unknown), Hanwen Wang, Atul Deshpande, Ravi Varadhan, Leisha A. Emens, Elizabeth M. Jaffee, Elana J. Fertig, Cesar A. Santa‐Maria, Aleksander S. Popel	4
3	Hypoxia induces ROS-resistant memory upon reoxygenation in vivo promoting metastasis in part via MUC1-C 2024 ·Nature Communications ·Inês Godet, (unknown), (unknown), (unknown), (unknown), (unknown), Michael Considine, (unknown), Jingyuan Zhang, (unknown), (unknown), (unknown), Genevieve Stein-O’Brien, Luciane T. Kagohara, Cesar A. Santa‐Maria, Elana J. Fertig, Daniele M. Gilkes	6
4	Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer 2023 ·JAMA Oncology ·Brian D. Lehmann, Vandana G. Abramson, Elizabeth Claire Dees, Payal D. Shah, Tarah J. Ballinger, Claudine Isaacs, Cesar A. Santa‐Maria, Hanbing An, Paula I. González-Ericsson, Melinda E. Sanders, (unknown), Richard G. Abramson, Quanhu Sheng, Chih–Yuan Hsu, Yu Shyr, Antonio C. Wolff, Jennifer A. Pietenpol	18
5	NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer 2023 ·Cancer Discovery ·Brandie C. Taylor, Xiaopeng Sun, Paula I. González-Ericsson, Violeta Sánchez, Melinda E. Sanders, (unknown), Susan R. Opalenik, Ann Hanna, (unknown), Luc Van Kaer, Henry Gómez, Claudine Isaacs, Tarah J. Ballinger, Cesar A. Santa‐Maria, Payal D. Shah, Elizabeth Claire Dees, Brian D. Lehmann, Vandana G. Abramson, Jennifer A. Pietenpol, Justin M. Balko	31
6	Exceptional responses to PARP inhibitors in patients with metastatic breast cancer in oncologic crisis 2023 ·Breast Cancer Research and Treatment ·Joyce Cheng, Jenna VanLiere Canzoniero, Seoho Lee, (unknown), (unknown), Cesar A. Santa‐Maria	1
7	A transcriptome-informed QSP model of metastatic triple-negative breast cancer identifies predictive biomarkers for PD-1 inhibition 2023 ·Science Advances ·(unknown), Hanwen Wang, Leisha A. Emens, Cesar A. Santa‐Maria, Aleksander S. Popel	16
8	Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancer 2022 ·iScience ·Hanwen Wang, Chen Zhao, Cesar A. Santa‐Maria, Leisha A. Emens, Aleksander S. Popel	31
9	The tumor microenvironment and triple-negative breast cancer aggressiveness: shedding light on mechanisms and targeting 2022 ·Expert Opinion on Therapeutic Targets ·(unknown), Vered Stearns, Cesar A. Santa‐Maria, Aleksander S. Popel	12
10	Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer 2022 ·Nature Cancer ·Laura M. Spring, Hyo S. Han, Minetta C. Liu, Erika Hamilton, Hanna Y. Irie, Cesar A. Santa‐Maria, James A. Reeves, Peng Pan, Ming Shan, Yongqiang Tang, Julie R. Graham, Sebastien Hazard, Leif W. Ellisen, Steven J. Isakoff	16
11	A Phase II Single-arm Study of Palbociclib in Patients With HER2-positive Breast Cancer With Brain Metastases and Analysis of ctDNA in Patients With Active Brain Metastases 2022 ·Clinical Breast Cancer ·Ami N. Shah, Cesar A. Santa‐Maria, Dhruvika Mukhija, Nikita Shah, (unknown), Priya Kumthekar, Kirsten B. Burdett, Shruti Chandra, Jenny C. Chang, (unknown), (unknown), Borko Jovanovic, Lorenzo Gerratana, William J. Gradishar, Massimo Cristofanilli	10
12	In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model 2019 ·Royal Society Open Science ·Hanwen Wang, Oleg Milberg, Imke H. Bartelink, Paolo Vicini, Bing Wang, Rajesh Narwal, Lorin Roskos, Cesar A. Santa‐Maria, Aleksander S. Popel	51
13	Impact of tissue-based genomic profiling on clinical decision making in the management of patients with metastatic breast cancer at academic centers 2017 ·Breast Cancer Research and Treatment ·Cesar A. Santa‐Maria, Megan Kruse, Paola Raska, (unknown), (unknown), (unknown), Jame Abraham, Sarika Jain, Rita Nanda, Alberto J. Montero	6
14	A pilot study of cabergoline for the treatment of metastatic breast cancer 2017 ·Breast Cancer Research and Treatment ·Ricardo Costa, Cesar A. Santa‐Maria, Denise Scholtens, Suneil Jain, Lisa Flaum, William J. Gradishar, Charles V. Clevenger, Virginia Kaklamani	16
15	Management of Metastatic HER2-Positive Breast Cancer: Where Are We and Where Do We Go From Here? 2016 ·PubMed ·Cesar A. Santa‐Maria, Lauren Nye, (unknown), (unknown), William J. Gradishar	33
16	Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy 2015 ·Clinical Cancer Research ·Cesar A. Santa‐Maria, Amanda L. Blackford, Anne Nguyen, Todd C. Skaar, Santosh Philips, Steffi Oesterreich, James M. Rae, Zeruesenay Desta, Jason Robarge, N. Lynn Henry, Anna Maria Storniolo, Daniel F. Hayes, Roger S. Blumenthal, Pamela Ouyang, Wendy S. Post, David A. Flockhart, Vered Stearns	18
17	Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate 2015 ·Clinical Cancer Research ·Preethi Korangath, Wei Wen Teo, Helen Sadik, Liangfeng Han, Noriko Mori, (unknown), Flonné Wildes, Santosh Kumar Bharti, Zhe Zhang, Cesar A. Santa‐Maria, (unknown), Chi V. Dang, Vered Stearns, Zaver M. Bhujwalla, Saraswati Sukumar	133
18	Breast cancer and immunology: biomarker and therapeutic developments 2015 ·Expert Review of Anticancer Therapy ·Cesar A. Santa‐Maria, (unknown), Sarika Jain, William J. Gradishar	10
19	Statins and Breast Cancer: Future Directions in Chemoprevention 2013 ·Current Breast Cancer Reports ·Cesar A. Santa‐Maria, Vered Stearns	10
20	PTEN, PIK3CA, p-AKT, and p-p70S6K Status 2010 ·American Journal Of Pathology ·Francisco J. Esteva, Hua Guo, Siyuan Zhang, Cesar A. Santa‐Maria, Steven Stone, Jerry S. Lanchbury, Ayşegül A. Şahin, Gabriel N. Hortobágyi, Dihua Yu	234

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact